BG106149A - Mutual prodrugs of amlodipine and atorvastatin - Google Patents

Mutual prodrugs of amlodipine and atorvastatin

Info

Publication number
BG106149A
BG106149A BG106149A BG10614901A BG106149A BG 106149 A BG106149 A BG 106149A BG 106149 A BG106149 A BG 106149A BG 10614901 A BG10614901 A BG 10614901A BG 106149 A BG106149 A BG 106149A
Authority
BG
Bulgaria
Prior art keywords
atorvastatin
amlodipine
relates
compositions
prodrugs
Prior art date
Application number
BG106149A
Other languages
Bulgarian (bg)
English (en)
Inventor
George Chang
Ernest Hamanaka
John LAMATTINA
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of BG106149A publication Critical patent/BG106149A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
BG106149A 1999-05-27 2001-11-26 Mutual prodrugs of amlodipine and atorvastatin BG106149A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13660899P 1999-05-27 1999-05-27
PCT/IB2000/000313 WO2000073298A1 (fr) 1999-05-27 2000-03-20 Promedicaments communs d'amlodipine et d'atorvastatine

Publications (1)

Publication Number Publication Date
BG106149A true BG106149A (en) 2002-05-31

Family

ID=22473579

Family Applications (1)

Application Number Title Priority Date Filing Date
BG106149A BG106149A (en) 1999-05-27 2001-11-26 Mutual prodrugs of amlodipine and atorvastatin

Country Status (41)

Country Link
US (1) US6486182B1 (fr)
EP (1) EP1180102B9 (fr)
JP (1) JP2003500487A (fr)
KR (1) KR20020012247A (fr)
CN (1) CN1352640A (fr)
AP (1) AP2001002345A0 (fr)
AR (1) AR022344A1 (fr)
AT (1) ATE268764T1 (fr)
AU (1) AU3313900A (fr)
BG (1) BG106149A (fr)
BR (1) BR0011006A (fr)
CA (1) CA2375372C (fr)
CO (1) CO5170457A1 (fr)
CZ (1) CZ20014229A3 (fr)
DE (1) DE60011424T2 (fr)
DK (1) DK1180102T3 (fr)
DZ (1) DZ3048A1 (fr)
EA (1) EA200101130A1 (fr)
EE (1) EE200100631A (fr)
ES (1) ES2220426T3 (fr)
GT (1) GT200000078A (fr)
HK (1) HK1046282A1 (fr)
HN (1) HN2000000075A (fr)
HR (1) HRP20010856A2 (fr)
HU (1) HUP0201433A2 (fr)
IL (1) IL145947A0 (fr)
IS (1) IS6135A (fr)
MA (1) MA26736A1 (fr)
MX (1) MXPA01012125A (fr)
NO (1) NO20015756L (fr)
OA (1) OA11950A (fr)
PA (1) PA8495701A1 (fr)
PE (1) PE20010169A1 (fr)
PL (1) PL353483A1 (fr)
PT (1) PT1180102E (fr)
SK (1) SK16792001A3 (fr)
SV (1) SV2002000082A (fr)
TN (1) TNSN00113A1 (fr)
TR (1) TR200103391T2 (fr)
WO (1) WO2000073298A1 (fr)
ZA (1) ZA200109691B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
GB0027410D0 (en) * 2000-11-09 2000-12-27 Pfizer Ltd Mutual prodrug of amlodipine and atorvastatin
US6737430B2 (en) 2000-11-09 2004-05-18 Pfizer, Inc. Mutual prodrug of amlodipine and atorvastatin
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
KR100958552B1 (ko) * 2001-06-11 2010-05-17 제노포트 인코포레이티드 Ｇａｂａ 유사체의 프로드러그, 이의 조성물 및 용도
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
DE10140421A1 (de) * 2001-08-17 2003-03-06 Bayer Ag Neue Kombination
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
CN102429882B (zh) 2004-11-04 2015-03-25 什诺波特有限公司 加巴喷丁前体药物持续释放口服剂型
EP1909848A2 (fr) * 2005-08-01 2008-04-16 PSivida Inc. Composes inhibiteurs de l'enzyme de conversion de l'angiotensine- inhibiteurs de la hmgcoa reductase
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
US8354116B2 (en) * 2007-06-18 2013-01-15 Biochemics, Inc. Bifunctional synthetic molecules
JP4905738B2 (ja) 2007-10-10 2012-03-28 Ｎｏｋ株式会社 アキュムレータ

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK161312C (da) 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5155120A (en) 1991-01-14 1992-10-13 Pfizer Inc Method for treating congestive heart failure
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.

Also Published As

Publication number Publication date
DE60011424D1 (de) 2004-07-15
PA8495701A1 (es) 2001-12-14
AR022344A1 (es) 2002-09-04
SK16792001A3 (sk) 2003-03-04
CZ20014229A3 (cs) 2003-01-15
BR0011006A (pt) 2002-02-19
GT200000078A (es) 2001-11-16
CO5170457A1 (es) 2002-06-27
IS6135A (is) 2001-10-30
NO20015756D0 (no) 2001-11-26
PL353483A1 (en) 2003-11-17
JP2003500487A (ja) 2003-01-07
MXPA01012125A (es) 2002-06-04
PT1180102E (pt) 2004-08-31
ES2220426T3 (es) 2004-12-16
EP1180102A1 (fr) 2002-02-20
TR200103391T2 (tr) 2002-04-22
AP2001002345A0 (en) 2001-12-31
DE60011424T2 (de) 2005-08-25
WO2000073298A1 (fr) 2000-12-07
IL145947A0 (en) 2002-07-25
HK1046282A1 (zh) 2003-01-03
HN2000000075A (es) 2001-02-02
EP1180102B1 (fr) 2004-06-09
TNSN00113A1 (fr) 2005-11-10
CA2375372A1 (fr) 2000-12-07
ZA200109691B (en) 2002-11-26
EA200101130A1 (ru) 2002-04-25
EE200100631A (et) 2003-02-17
US6486182B1 (en) 2002-11-26
KR20020012247A (ko) 2002-02-15
CA2375372C (fr) 2007-01-09
MA26736A1 (fr) 2004-12-20
CN1352640A (zh) 2002-06-05
NO20015756L (no) 2002-01-24
DK1180102T3 (da) 2004-09-06
HUP0201433A2 (en) 2002-08-28
HRP20010856A2 (en) 2002-12-31
AU3313900A (en) 2000-12-18
EP1180102B9 (fr) 2005-03-02
ATE268764T1 (de) 2004-06-15
SV2002000082A (es) 2002-02-05
DZ3048A1 (fr) 2004-03-27
PE20010169A1 (es) 2001-02-10
OA11950A (en) 2006-04-13

Similar Documents

Publication Publication Date Title
BG106128A (en) Mutual salt of amlodipine and atorvastatin
BG106149A (en) Mutual prodrugs of amlodipine and atorvastatin
FR2780730B1 (fr) Compositions biphasiques injectables, notamment utiles en chirurgies reparatrice et esthetique
PL339092A1 (en) Therapeutic compositions containing amlodipin and atorvastatin
BR9813154A (pt) Compósitos de fibra celulósica
MY121008A (en) Combination therapy comprising atorvastatin and an antihypertensive agent.
IS5941A (is) Píperidín sem CCR5 stillar
YU2700A (sh) Farmaceutska kombinacija koja obuhvata amlodipin i statin jedinjenja
AUPQ463799A0 (en) Fire resistant compositions
BG102589A (en) 3-azetidinylalkylpiperidines or -pyrrolidines as tachykin antagonists
GR1004124B (el) Ασπαρτικο παραγωγο της αμλοδιπινης.
LU90584B1 (de) Drahtfaser
DE69929024D1 (de) Immunschwächevirus Stamm FIV-141 der Katze und dessen Verwendungen
IS4783A (is) 1,4 -Díhýdrópýridín efnasambönd sem mótlyf gegn kínínseinkun
ECSP003493A (es) Profarmacos mutuos de amlodipino y atorvastatina
IL136119A0 (en) Flame resistant polyolefin compositions and methods for the preparation thereof
EE200200267A (et) Asendatud 1,2,3,4,5,6-heksahüdro-2,6-metano-3-bensasotsiinid ja nende kasutamine ravimina
ECSP003497A (es) Sal mutua de amlodipino y atorvastatina
TW413007U (en) Improved structure of stove for burning paper money for the dead
HUP0200148A3 (en) Use of n-(3',4'-dimethoxy-cinnamoyl)-anthranilic acid for the prevention or reduction of cardiovascular events associated with coronary intervention
TW444833U (en) High tensile bolt set
IT1313237B1 (it) Componente strutturale multifunzionale per quadri elettrici,centralini e simili.
AUPQ065499A0 (en) Modified worker operationin textile carding
HN1996000076A (es) Formulaciones de quinolona inyectables